Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions.
The last earnings update was 26 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Capricor Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Capricor Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Capricor Therapeutics's earnings are expected to grow by 14.1% yearly, however this is not considered high growth (20% yearly).
Capricor Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Capricor Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Capricor Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Capricor Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Capricor Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Capricor Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Capricor Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has been the key negotiator in the licensing agreements, which have provided to Capricor its intellectual property estate, as well as spearHeading Capricor’s fundraising efforts. She served as the Acting Chief Executive Officer of Capricor Therapeutics, Inc. She served as the Chief Executive Officer at Nile Therapeutics, Inc. Dr. Marbán’s scientific background is in cardiac physiology, an area in which She worked for two years as a postdoctoral fellow in Cardiology at the Johns Hopkins University, studied novel treatments for Myocardial Infarction (MI) in animal models. After a year on the faculty in the Department of Pediatrics at Johns Hopkins, Dr. Marbán joined the biotech start up company Excigen, Inc. as its Vice President for Business Development. In 2005, she was promoted to Vice President for Operations, in which she was responsible for raising capital from Medtronic Corporation through a Series A-2 Preferred Stock financing round. She serves as a Director of Capricor Therapeutics, Inc. since November 2013. She served as a Director of Nile Therapeutics, Inc. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. She advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure at Johns Hopkins University (“JHU”). Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.
Linda's compensation has increased whilst company is loss making.
Linda's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Capricor Therapeutics management team is about average.
Co-Founder & Chairman of Scientific Advisory Board
CFO & Corporate Treasurer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Capricor Therapeutics board of directors is about average.
Board of Directors
Co-Founder & Chairman of Scientific Advisory Board
What Kind Of Investor Owns Most Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)?
A look at the shareholders of Capricor Therapeutics, Inc. … With a market capitalization of US$20m, Capricor Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Capricor Therapeutics
Based On Its ROE, Is Capricor Therapeutics, Inc. (NASDAQ:CAPR) A High Quality Stock?
Capricor Therapeutics has a ROE of 5.4%, based on the last twelve months. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.054 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
One Thing To Remember About The Capricor Therapeutics, Inc. (NASDAQ:CAPR) Share Price
The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Reflect Performance?
Linda Marbán became the CEO of Capricor Therapeutics, Inc. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Linda Marbán's Compensation Compare With Similar Sized Companies?
Could Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Investor Composition Influence The Stock Price?
The big shareholder groups in Capricor Therapeutics, Inc. … With a market capitalization of US$16m, Capricor Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Capricor Therapeutics
How Financially Strong Is Capricor Therapeutics, Inc. (NASDAQ:CAPR)?
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt
How Good Is Capricor Therapeutics Inc (NASDAQ:CAPR), When It Comes To ROE?
Our data shows Capricor Therapeutics has a return on equity of 18% for the last year. … That means that for every $1 worth of shareholders' equity, it generated $0.18 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
I am going to take a deep dive into Capricor Therapeutics Inc’s (NASDAQ:CAPR) most recent ownership structure, not a frequent subject of discussion among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.
Can Capricor Therapeutics Inc (NASDAQ:CAPR) Continue To Outperform Its Industry?
Capricor Therapeutics Inc (NASDAQ:CAPR) delivered an ROE of 23.03% over the past 12 months, which is an impressive feat relative to its industry average of 18.07% during the same period. … Sustainability can be gauged by a company’s financial leverage – the more debt it has, the higher ROE is pumped up in the short term, at the expense of long term interest payment burden. … See our latest analysis for Capricor Therapeutics
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.